- Advertisement -spot_img
Sunday, November 28, 2021

‘Time Gap’ may increase between two doses of Covishield, central government will take decision next week

New Delhi. According to reports, an Expert Panel of the Government of India is now considering increasing the time interval between two doses of Oxford-AstraZeneca’s Covieshield vaccine. Yes, according to some media reports, this expert panel is now reviewing data from international studies which point out that if the interval between the two doses of the corona vaccine is prolonged, it improves the efficacy of the vaccine it happens.

The official committee can take a decision on this next week. Let us know that the interval between two doses of Covicield produced by Pune’s Serum Institute of India (SII) was increased from four-six weeks to six-eight weeks in April Was.

Vaccine more effective than more frequent intervals:

Experts also believe that such a step may reduce the pressure on the supply chain of the vaccine. Dash has now decided to include all adults in its mass immunization program. In March, a study published in The Lancet magazine said that 81 in Covishield. 3% is efficacy and its second dose is administered two weeks apart. But in contrast, researchers found Covishield’s efficacy at that interval time to be only 55.1%. According to data from tests in the UK and Brazil, the vaccine was given 90% when given as a second dose at least a month or a few days later. Is effective till

Read Also: Covid-19 new guideline in Delhi, 14 days quarantine required for those coming from these states

Effective in other countries as well:

But right now there is not enough data to work on this idea. In countries such as the UK and Canada, two doses of the vaccine are being given at intervals of 12 weeks and 16 weeks respectively. Experts there point out that the vaccine leads to better immune response with a lag in the time period. Now if the gap between the two doses of the vaccine in India increases, it will help the country on two fronts. First, that there may be a slight reduction in the skyrocketing demand for the Corona vaccine to all adults starting May
1. This will help Covishield of SII and Covaxin of Bharat Biotech to become their productions. Secondly, now if the crowd gets reduced for the second dose, the health officer will be focusing on vaccinating more beneficiaries with the first dose. Will be able to

Read Also:  UK resists new bans, but calls for accelerated spread of COVID

What is AstraZeneca says:

If we look at this, recent data from the Korea Disease Control and Prevention Agency (KDCA) have shown that the AstraZeneca vaccine is 86.0% effective in people aged over 60 at least two weeks after the first dose. AstraZeneca stated on its website, “In the third phase clinical analysis of the UK, Brazil and South Africa confirmed the vaccine to be safe and effective, 22 days after the first dose and any serious illness. Haven’t seen

In the website, if we look at the results of February 3, the vaccine demonstrated an efficacy of 76% after the first dose interval, which maintained the required immunity before the second dose. At the same time, with an interval of 12 weeks or more, the efficacy of this vaccine increased to 82%. “

Significantly, by May 6, India’s immunization coverage had crossed 18.244 crore, with over nine lakh beneficiaries in the age group of 18-44 receiving their first vaccine.

World Nation News Deskhttps://www.worldnationnews.com
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -

Leave a Reply